QCM
NBIX icon

Quantinno Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Quantinno Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4M Buy
79,655
+10,156
+15% +$1.51M 0.02% 867
2026
Q1 		$9.16M Buy
69,499
+42,508
+157% +$5.64M 0.02% 905
2025
Q4 		$3.83M Buy
26,991
+10,786
+67% +$1.56M 0.01% 1121
2025
Q3 		$2.27M Buy
16,205
+3,358
+26% +$455K 0.01% 1184
2025
Q2 		$1.61M Buy
12,847
+2,240
+21% +$257K 0.01% 1156
2025
Q1 		$1.17M Buy
10,607
+6,644
+168% +$842K 0.01% 1109
2024
Q4 		$541K Buy
3,963
+1,724
+77% +$213K 0.01% 1211
2024
Q3 		$258K Buy
2,239
+448
+25% +$61.4K ﹤0.01% 1313
2024
Q2 		$247K Buy
1,791
+154
+9% +$21.1K ﹤0.01% 1212
2024
Q1 		$226K Buy
+1,637
New +$224K ﹤0.01% 1156

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quantinno Capital Management's NBIX Position: Q2 2026 in Review

Quantinno Capital Management increased its Neurocrine Biosciences (NBIX) stake by 15% in Q2 2026, buying an estimated $1.51M and bringing the position to 79,655 shares worth $13.4M. The position accounts for 0.02% of the portfolio, ranked #867.

Quantinno Capital Management first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Quantinno Capital Management held 79,655 shares of Neurocrine Biosciences worth $13.4M as of Q2 2026.
  • Quantinno Capital Management bought 10,156 Neurocrine Biosciences shares in Q2 2026, an estimated $1.51M.
  • Neurocrine Biosciences made up 0.02% of Quantinno Capital Management's portfolio in Q2 2026, its #867 holding.
  • Quantinno Capital Management first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.